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Introduction
Ovarian cancer is the fifth leading cause of death among women, and is the most common cause arising from gynecological malignancies (1) . Although progress has been made in the treatment of epithelial ovarian cancer (EOC) by improved surgical debulking and the introduction of platinum-taxane regimens, overall five-year survival is only 29% in advanced-stage disease (2) (3) (4) (5) (6) .
This low survival rate is due to its frequent diagnosis at an advanced stage and by intrinsic and acquired resistance to platinum-based chemotherapy. In the recurrent disease setting, those patients who experience progression through first-line, platinum-based therapy (platinum-refractory), or those who experience relapse within six months of receiving platinum therapy (platinum-resistant) are typically treated with a second-line non-platinum-based regimen, such as single-agent doxorubicin (7) gemcitabine (8) , paclitaxel, topotecan (9) , vinorelbine (10) or trabectedin plus pegylated liposomal doxorubicin (11) . Agents yielding responses in the range of 15-20% that last a median of approximately four months, emphasize the great need for novel effective therapeutic strategies for its management (12) (13) (14) (15) .
DNA structure features two well-defined clefts known as the major and minor grooves, and DNA-binding proteins and drugs usually make contacts with the sides of the bases exposed in both grooves (16, 17) . The DNA major groove is a site of attack for cisplatin and many alkylating agents, and when cisplatin binds to DNA three types of lesions can be formed on purine bases: monoadducts, and intra-and interstrand crosslinks. On the other hand, other anti-tumor drugs including mitomycin C, chromomycin A 3 and ecteinascidins, bind to the minor groove (18) . One of the best examples is trabectedin (Yondelis ® ), which reacts with certain guanines in the minor groove of DNA to form a covalent bond (19) (20) (21) . The adduct is stabilized by van der Waals interactions with nucleotides in the opposite DNA strand, creating the equivalent of a functional interstrand crosslink (22) . Lurbinectedin (PM01183) is a new synthetic alkaloid that is structurally related to ecteinascidins (23) , which, with the exception of a module addition (ring C), confer important pharmacokinetic and pharmacodynamics properties benefits as well intrinsic activity (24) (25) (26) .
Establishment of preclinical models phenocopying patients' primary tumor features, which accurately reflect phenotypic, genotypic and tumor chemotherapy response behavior, is a basic step on the way to identifying novel therapeutic targets and for testing novel treatments (27, 28) . Several lines of evidence indicate that engrafting primary tumor tissues orthotopically into immune-deficient mice (termed "tumor grafts") may be outstandingly valuable preclinical models for new drug development, and for reducing the high failure rate that exists in translating preclinical results to patients (29) (30) (31) (32) (33) .
Here we report the establishment and characterization of a serially transplantable, orthotopic, subject-derived epithelial ovarian tumor graft that retains crucial characteristics of the original primary tumor specimen, and its further development as an in vivo cisplatin-resistance tumor model. We demonstrate in engrafted pre-clinical models that lurbinectedin, a new minor groove DNA binder, is effective in the treatment of experimental ovarian tumors as a single or a combined-cisplatin agent. Overall, we present evidence of the efficacy of a therapeutic strategy based on the idea that a combination of two drugs that bind differentially to each DNA groove could overcome frequent cisplatin resistance in advanced-stage ovarian cancer.
Results
Orthotopic model of epithelial ovarian cancer mimics the histopathological characteristics of primary patients' tumors.
Primary tumors engrafted in the ovarian surface of athymic female mice (named OVA1X) grew as large solid masses. Ovarian infiltration and neighboring organ invasion or ascitis were not seen in any of the implanted animals ( Fig 1A) . The engrafted rate was close to 95% in all mouse-to-mouse passages, with a mean time of ca. 1000 to 1500 mm 3 during the first six passages of 84 ± 8 days.
As shown in Fig 1A, a very high histological correlation was found between primary and engrafted tumors. Indeed, OVA1X had a typical serous adenocarcinoma appearance showing high cellularity, cellular papillae formation and irregular slit-like spaces, and it remained stable throughout multiple rounds of serial mouse-to-mouse transplantation. Ki-67 immunostaining revealed a similar proliferative rate in primary and engrafted tumors, and they both preserved the same cytokeratin 7 (CK7) and Wilm's tumor susceptibility gene 1 (WT1) immunostaining pattern. Engrafted OVA1X tumor also retained their levels of positive immunostaining for estrogen receptor through mouse-tomouse passages. Ascitis or synchronic peritoneal implants arising through tumor perpetuation were rarely identified in mice (data not shown).
Cisplatin treatment of engrafted tumor recapitulates characteristic features of primary tumor response in mice.
OVA1X-implanted mice were treated with low (2 mg/kg), intermediate (3.5 mg/kg) and high (5 mg/kg) doses of cisplatin, and short-and long-term responses were evaluated (Fig 1B) . Low or intermediate doses of cisplatin were associated with a good short-term response, characterized by significant tumor weight reduction relative to the control group, whilst there was a complete response at high doses. Long-term response was investigated in a subgroup of mice (n=4-6 mice/treatment/dose) that were kept alive for a post-chemotherapy follow-up of 6-12 months.
Tumors relapsed in 5 of 10 (50%) mice treated with 2 mg/kg and in 3 of 10 (30%) treated with 3.5 mg/kg at six months, whereas all animals treated with 5 mg/kg were disease-free after a 12-month follow-up. Post-chemotherapy, histological and immunohistochemical analysis of relapsed masses exhibited a viable serous adenocarcinoma that preserved the morphology and the main immunophenotypical characteristics of untreated engrafted tumors.
In vivo development of a cisplatin-resistant engrafted tumor model that recapitulates cisplatin primary tumor behavior response is a feasible model for pharmacological drug evaluations.
The general approach use to obtain the cisplatin-resistant engrafted tumor model is illustrated in Fig 1C. OVA1X-implanted mice were initially treated with low doses (2 mg/kg) of cisplatin. When tumors relapsed, they were harvested and implanted in new animals (mouse-to-mouse passage).
The process was repeated up to five times by treating tumor-bearing mice with stepwise increasing doses of cisplatin (Fig 1C) . A progressively shortened time-lag between treatment and tumor relapse was noted for the three independent tumor lines (named OVA1XR-L1, -L2, and -L3) generated after iterative cycles of treatment. Indeed, a shortened time-lag was mainly noted after the third or fourth cycle, and became stabilized (41 ± 6.1 days) subsequently for successive cycles of cisplatin treatment (Fig 1D, left) . Next, we evaluated the levels of cisplatin tumor resistance by comparative assays of OVA1X and each of the three independent lines of resistant tumors and homogeneous resistance was reproduced with each individual OVA1XR tumors (Fig 1D, right) .
Thus, we selected OVA1XR-L2 for all further experiments, hereafter referred to as OVA1XR. and lurbinectedin+cisplatin, respectively (Fig 2A, left) . Although, as single agents both cisplatin and lurbinectedin had a significant response with respect to the placebo-treated animals, non significant differences were observed among both individual treatments. 
P=0.002).
Histopathological changes were assessed for the different treatments within the tumor as surrounding stromal tissue in both cisplatin-sensitive (Fig 2A, right, (Fig 2B) .
To investigate the long-term response a subgroup of treated mice (n=4-6 mice/group) were kept alive post-chemotherapy. Thus, OVA1XR tumor relapse took place over a period of 42 days in all cisplatin-treated mice, whereas in cisplatin-sensitive OVA1X regrowth was found in only one cisplatin-treated mouse after eight months follow-up. At sacrifice of OVA1XR, significant differences were found in the weight and histology of relapsed masses (-RL) for lurbinectedinbased treatments compared to the cisplatin-RL group (lurbinectedin-RL vs. cisplatin-RL, P=0.0020; or lurbinectedin+cisplatin-RL vs. cisplatin-RL, P=0.0008) (Fig 2C, upper) . Furthermore, combined lurbinectedin+cisplatin treatment was more active than lurbinectedin monotherapy (P=0.046), suggesting a long-term synergistic anti-tumor response for combined therapy. This finding is reinforced by the histology of lurbinectedin+cisplatin-RL masses (Fig 2C, lower) . Together, although our results demonstrated the efficacy of lurbinectedin treatment in the treatment of cisplatin-sensitive and cisplatin-resistant orthotopic engrafted tumor models, it is of note that they also suggest a synergistic effect with cisplatin in cisplatin-resistant OVA1XR.
Histopathological tumor regression criteria are associated with treatment response in cisplatin-sensitive OVA1X and cisplatin-resistant OVA1XR tumors.
tumors (34) (35) (36) (37) . Supplementary Table 1 and Table 1 show extensive analysis of regression criteria for both OVA1X and OVA1XR, to establish whether they are suitable indicators of treatment response, as described for primary neoadjuvant epithelial ovarian cancer (38) . Based on these criteria, a moderate histopathological response was observed in OVA1X for single cisplatin and lurbinectedin treatments, while a good response with respect to regression criteria was found for the combined treatment (Supplementary Table 1 ). Taken together, the tumor response and the histopathological regression criteria were evidence of the relevance of the combined treatment in cisplatin-sensitive OVA1X.
In this context, in cisplatin-resistant OVA1XR tumor a good histopathological response was confirmed for the combined lurbinectedin+cisplatin treatment (Table 1) . Moreover, the relevance of combined treatments was reinforced by the observation that the histopathological response was maintained in relapsed masses ( Table 1 We found that 24 hours after treatments of the A2780 xenografts, the anti-phospoHistone H3 (S10)(H3S10ph) mitosis marker significantly decreased in cisplatin (P=0.007), lurbinectedin (P=0.002) or combined (P<0.001) treatments compared with placebo-treated tumors (Fig. 4A) . In fact, the decrease was significantly greater for the combined treatment than for each single therapy (lurbinectedin+cisplatin vs. lurbinectedin, P=0.005; or vs. cisplatin, P=0.015).
Additionally, a proapoptotic effect was associated with lurbinectedin treatments. Thus, a 6.7-fold increase in the number of apoptotic cells (by TUNEL assay) was observed in combined lurbinectedin+cisplatin (P=0.013) treatment compared with the placebo group, and 3.0-fold and 3.7-fold increases with respect to cisplatin and lurbinectedin, respectively (Fig. 4C, left) .
Likewise, antiproliferative and proapoptotic effects were confirmed in both engrafted orthotopic models. In OVA1XR (Fig. 4B) This effect was also maintained in relapsed tumor masses (lurbinectedin+cisplatin-RL vs. cisplatin-
RL, P=0.005; or vs. lurbinectedin, P=0.012). Apoptotic drug-induction was assessed in OVA1X and
OVA1XR by immunodetection in paraffin-embedded tissues of caspase-3, an early and specific apoptotic marker. In cisplatin-sensitive OVA1X, non-significant differences for the proapoptoticinduced effect were observed for the single treatments (cisplatin, 6.3-fold; lurbinectedin, 7.1-fold; (Fig 4C, right) . Whereas in cisplatin-resistant OVA1XR tumor the strong proapoptotic effect was noted for lurbinectedin (4.2-fold induction relative to the placebo, P=0.014; and 2.8-fold with respect to cisplatin, P=0.007), cisplatin retaining a moderate capability of inducing apoptosis in OVA1XR tumors (1.5-fold induction relative to placebo, P=0.036) (Fig 4C, right) . We did not analyze apoptosis induction in the combined treatment because the extensive histopathological regression prevents the reliable interpretation of the caspase cleaved apoptosis assay (data not shown).
P=0.45)
Finally, we investigated whether lurbinectedin treatments affected the morphology of the mitotic spindle by double immunofluorescence staining with α-tubulin (red staining), a protein localized in the spindle, combined with staining with the mitosis marker histone H3S10ph (green staining) (Fig 4D and Supplementary Fig 1) . treatment, in A2780-derived xenografts and both engrafted orthotopic models (Fig 4D) .
DISCUSSION
In this work we report the generation and characterization of a serous ovarian cancer model based on orthotopic tumor implantation in nude mice, and its further in vivo development as a tumor model of cisplatin resistance. Next, as preclinical models, we demonstrate that lurbinectedin, a new synthetic alkaloid binder to the DNA minor groove, is effective either in the treatment of cisplatin-sensitive and cisplatin-resistant ovarian tumors. So, our results show that the combination of two compounds that differentially bind the DNA major and minor grooves should be a useful treatment strategy for EOC patients, and suggest its importance for overcoming cisplatinresistance.
Recent data suggest an overall success rate of 10% for oncology products in clinical development, being one of the reasons attributed to this failure the fact that preclinical models used frequently do not predict clinical results (31) . Currently, preclinical in vivo drug development is mainly realized in subcutaneous (s.c.) tumor xenografts generated after cell line injection, or in some cases after s.c. engraftment of primary tumor (29, 32, 33) , and pure primary orthotopic tumor-based models have rarely been used. Few such tumor models are available: because surgery is often complex, small numbers of mice are used per study, and the models are more expensive (28) . Here, we demonstrate that these orthotopic-based pre-clinical ovarian tumor models, which reproduce primary tumor properties, are outstanding resources for the development of new drug therapies. They would also be very valuable for exploring new therapeutic applications for drugs that are currently approved for use in humans, as we recently reported in MSI+ colorectal tumors with enoxacin (39) . Thus, assessed chemotherapy responses in cisplatin-sensitive and cisplatin-resistant tumor models that maintain the morphological, histological and genetic characteristics of patients' tumors, including the behavior of the stromal component and the tissue architecture, may improve pre-clinical drug translation to patients.
To overcome cisplatin resistance and reduce the side effects, new agents should have different mechanisms of action and should be non-cross-resistant with platinum (40) . Structurally, the DNA duplex gives rise to two well-defined clefts known as the major and minor grooves (25) .
While the DNA major groove represents a site of attack for cisplatin and many alkylating agents, other anti-tumor drugs such as ecteinascidins, mitomycin C and chromomycin A3 bind to the minor groove (16, 17) . Our work with the new synthetic alkaloid lurbirnectedin strongly suggests that strategies based on dual major and minor DNA groove-targeted therapies should be useful for treating cisplatin-resistant/refractory cases of ovarian carcinomas. Further studies in these models will allow a deeper insight into the cooperative mechanism of action among cisplatin and lubirnectedin, and enable their combined properties with other drugs such olaparib, temozolamide, doxorrubicine, etc. to be evaluated. Although, lurbinectedin is structurally similar to trabectedin (38) . The size of the residual tumor remaining after debulking surgery is known to be an important prognostic factor (42) . Likewise, we demonstrate in both tumor models that the size of the residual masses and the abundance of regressive criteria correlate with response. The strong correlation between our preclinical tumor models and clinical settings in terms of tumor progression and response to chemotherapy, strongly argues in favor of conducting clinical lurbinectedin trials in resistant/refractory epithelial ovarian cancer.
In conclusion, we have demonstrated that lurbinectedin, a drug targeting the minor DNA groove, is active and in vivo synergizes with cisplatin, which targets the major DNA groove, in the treatment of orthotopic cisplatin-sensitive and cisplatin-resistant patient-derived preclinical tumor models. Overall, our results provide solid evidence supporting clinical trials with lurbinectedin alone or in combination with cisplatin in advanced EOCs. 
Material and Methods

Drugs and cell lines:
Determination of tumor proliferation, apoptosis and angiogenesis: Proliferation was assessed
by quantifying the anti-phospo-Histone H3 (S10) (Millipore) mitosis marker as described (48) . Supplementary Table 1 and Table 2 ). cisplatin-RL, lurbinectedin-RL, lurbinectedin+cisplatin-RL, tumor relapsed after cisplatin, lurbinectedin or combined treatments, respectively. *, P<0.05. 
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